Hemant Surgical Industries Ltd — Important, 09-06-2026: Company Update

502,5th Floor, Esctacy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.

Tel. : +91-22-2591 2747

Email: info@hemantsurgical.com, sales@hemantsurgical.com, Web : www.hemantsurgical.com

CIN: L33110MH1989PLC051133

June 09, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai 400001

Scrip code: 543916

Sub.: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015 – Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015, please find enclosed Press Release being issued by the Company titled

"Hemant Surgical Strengthens Healthcare Portfolio Through Strategic Acquisition of

Majority Stake in Lifesenz Cancer Research Labs".

Request you to take the same on record.

Thanking you,

Yours faithfully,

For Hemant Surgical Industries Limited

Hanskumar Shamji Shah

Managing Director

DIN: 00215972

Email id: hanskumar@hemantsurgical.com

----------------Page (0) Break----------------

502,5th Floor, Esctacy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.

Tel. : +91-22-2591 2747

Email: info@hemantsurgical.com, sales@hemantsurgical.com, Web : www.hemantsurgical.com

CIN: L33110MH1989PLC051133

Press Release

Hemant Surgical Strengthens Healthcare Portfolio Through Strategic

Acquisition of Majority Stake in Lifesenz Cancer Research Labs

Mumbai (June 09, 2026): Hemant Surgical Industries Limited [BSE Scrip Code:

543916] ("Hemant Surgical" or "the Company"), an internationally acclaimed

manufacturer of medical disposable, surgical equipment, pharmaceutical products,

and exporter/Importer as well as a marketer in India and around the world, has

completed the strategic acquisition of a majority stake (66.66%) in Lifesenz Cancer

Research Labs Private Limited ("Lifesenz"), a company focused on precision oncology

and personalized cancer treatment solutions for an amount of Rs. 19.98 Crores,

making Lifesenz a subsidiary of the Company with effect from June 01, 2026.

Expanding into a High-Growth Segment of Healthcare

Globally oncology remains one of the fastest-growing healthcare segments, driven by

increasing cancer incidence, growing demand for personalized treatment

approaches, and continued innovation in cancer care. Lifesenz operates in the field

of precision oncology by assisting clinicians with patient-specific treatment selection

through advanced ex-vivo chemo-sensitivity analysis using patient-derived 3D

cancer cell models. This approach enables oncologists to evaluate the likely

effectiveness of different treatment options on a patient's own cancer cells before

therapy is administered, supporting more informed clinical decision-making.

The acquisition represents an important step in the Company’s long-term strategy to

expand beyond traditional healthcare distribution and participate in emerging areas

of advanced diagnostics and precision medicine.

Building on Existing Strengths

Hemant Surgical has built a strong presence in the healthcare sector through its

established distribution capabilities, customer relationships, institutional

engagement, and market reach. The integration of Lifesenz's scientific and oncology-

focused capabilities with the Company’s healthcare ecosystem is expected to create

opportunities to:

✓ expand the Company's participation in specialized healthcare and oncology

markets.

✓ strengthen relationships with hospitals, clinicians, and healthcare

institutions.

✓ enhance the Company's portfolio with differentiated healthcare solutions.

✓ increase exposure to innovation-led segments with long-term growth

potential.

✓ create a platform for future expansion in precision medicine and advanced

cancer care services.

The Company believes the acquisition creates a compelling strategic fit with its

existing healthcare platform.

----------------Page (1) Break----------------

502,5th Floor, Esctacy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.

Tel. : +91-22-2591 2747

Email: info@hemantsurgical.com, sales@hemantsurgical.com, Web : www.hemantsurgical.com

CIN: L33110MH1989PLC051133

Established Industry Collaborations

As awareness of personalized cancer treatment continues to grow, management

believes the demand for technologies that improve treatment selection and clinical

outcomes is likely to increase over the coming years.

Lifesenz has developed collaborations with hospitals, oncologists, research

institutions, and other healthcare stakeholders. The Company believes these

relationships provide a foundation for scaling operations and expanding adoption of

precision oncology solutions in India.

Long-Term Value Creation Approach

The Company acknowledges that Lifesenz is currently in a growth and development

phase, reflecting investments in research, technology, infrastructure, and market

expansion and will take some time to break even and eventually add financial

synergies to the Company. The acquisition has, therefore, been evaluated through a

long-term strategic and objective lens by the Board of Directors of the Company and

taking into account the strategic advantages that accrue to the Company

immediately rather than near-term profitability metrics. The acquisition has been

completed purely on arm’s length basis, considering the best interest of the

Company.

The Company intends to take following initiatives to enable Lifesenz to contribute

meaningfully to future revenue growth and long-term shareholder value creation as

the business matures:

✓ Scaling operational capabilities.

✓ Strengthening clinical and institutional collaborations.

✓ Expanding patient adoption.

✓ Increasing commercialization opportunities.

✓ Supporting innovation in precision oncology.

Management Commentary

Commenting on the acquisition, Mr. Hanskumar Shamji Shah, Managing Director of

Hemant Surgical Industries Limited stated:

"Precision oncology is an area of significant clinical importance and growing global

relevance. The acquisition of Lifesenz reflects our commitment to participate in the

future of healthcare. By combining Lifesenz's scientific expertise with Hemant

Surgical's established healthcare platform, we are creating a foundation for

long-term growth while contributing to improved patient care outcomes. We

believe this investment positions the Company to participate in a transformative

segment of healthcare and create sustainable value for our stakeholders."

----------------Page (2) Break----------------

502,5th Floor, Esctacy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.

Tel. : +91-22-2591 2747

Email: info@hemantsurgical.com, sales@hemantsurgical.com, Web : www.hemantsurgical.com

CIN: L33110MH1989PLC051133

About Hemant Surgical Industries Limited

Hemant Surgical Industries Limited is a BSE SME Listed, CDSCO compliant

Company established in 1985 in Mumbai dedicated to importing, manufacturing,

and marketing premium quality surgical and pharmaceutical products at economical

prices, making advanced healthcare accessible across India. The Company continues

to focus on expanding its healthcare presence, pursuing growth opportunities, and

creating long-term value for shareholders through strategic initiatives and

operational excellence.

Forward-Looking Statement

This press release contains forward-looking statements regarding future business

prospects, expected synergies, growth opportunities, and market developments.

Actual results may differ materially due to market conditions, regulatory

developments, execution risks, and other factors beyond the Company's control.

For further details please contact:

502, 5th Floor, Ecstasy Business Park, Near City of Joy,

JSD Road, Mulund West, Mumbai, Maharashtra – 400080;

+91-22-2591 2747

cs@hemantsurgical.com /info@hemantsurgical.com

----------------Page (3) Break----------------